Upadacitinib Sustains Vitiligo Repigmentation to 76 Weeks
Week-76 data from the phase 3 Viti-Up trials show upadacitinib drove continued facial and total-body repigmentation in nonsegmental vitiligo, with a UVB substudy reporting 63% reaching T-VASI 50.